RESUMO
This chapter discusses the barriers related to treating substance use disorders (SUD) in primary-care building an argument that stigma is the largest health disparity left to overcome in this setting. Reviewing the history of treatment in primary-care, common medications prescribed, laws, and regulations that make this care possible in this setting. Owing to the sheer numbers of people with SUD and mental health concerns, primary-care and their related payers must recognize for many regions of the United States those community needs are related to the diagnosis and treatment of SUDs and their related behavioral and physical health problems.
Assuntos
Transtornos Relacionados ao Uso de Substâncias , Humanos , Estados Unidos , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Saúde Mental , Atenção Primária à SaúdeRESUMO
Insomnia impairs quality of life and is associated with an increased risk for physical and mental health problems and substance misuse. Here's how you can help.
Assuntos
Qualidade de Vida , Distúrbios do Início e da Manutenção do Sono , Humanos , LongevidadeRESUMO
INTRODUCTION: This brief report describes how a family medicine residency practice (FMRP) leveraged a resident-led quality improvement project and a grant-funded Addiction Integrated Care Team (AICT) to initiate an office-based opioid treatment (OBOT) program to provide medications for opioid use disorder during the COVID-19 pandemic. METHOD: In 2020, the practice experienced four disruptors that shifted motivation for practice development: (a) The COVID-19 pandemic demanded rapid change in primary care processes/staffing, including pivoting to telehealth/remote practice. (b) The practice's transition to a federally qualified community health center model meant a shift in organizational priorities that required offering OBOT services. (c) External grant resources became available through the AICT program to support practice core for OBOT, and 10 implementation strategies were utilized. (d) A resident champion implemented an OBOT quality improvement project. RESULTS: These efforts resulted in the practice offering the OBOT program and 18 patients receiving OBOT from January 2020 to February 2021, with 10 of 18 patients engaged for 12 months or longer. Further, the cumulative adoption and reach from January 2020 through September 2022 was 15 faculty and 14 residents becoming prescribers and 101 patients served within the OBOT program, respectively. DISCUSSION: FMRPs striving for significant practice transformation, such as implementing an OBOT program during a pandemic, may benefit from synergistic guidance and resources including established theory, strategies from the implementation science literature, and resident-led quality improvement efforts. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
Assuntos
Buprenorfina , COVID-19 , Internato e Residência , Humanos , Analgésicos Opioides/uso terapêutico , Buprenorfina/uso terapêutico , Tratamento de Substituição de Opiáceos/métodos , Medicina de Família e Comunidade/educação , PandemiasRESUMO
Monitoring patients' health, mobility, mentation, and ability to maintain social connections can help you promote healthy aging for your older patients.